Rubraca® (rucaparib) – Voluntary indication withdrawal
June 10, 2022 - The FDA approved a voluntary indication withdrawal for Clovis Oncology’s Rubraca (rucaparib), for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapies.
Top